why choose us

300×250 Ad Slot

Drug FDA Status

Showing 40 of 158 result(s) (Page 4 of 16)
Drug Name: Modeyso

Active Ingredient: dordaviprone

Approval Date: 2025-08-06

Description: To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
Drug Trials Snapshot

Drug Name: Vizz

Active Ingredient: aceclidine

Approval Date: 2025-07-31

Description: To treat presbyopia

Drug Name: Sephience

Active Ingredient: sepiapterin

Approval Date: 2025-07-28

Description: To treat hyperphenylalaninemia in patients with sepiapterin-responsive phenylketonuria, in conjunction with a phenylalanine-restricted diet
Drug Trials Snapshot

Drug Name: Anzupgo

Active Ingredient: delgocitinib

Approval Date: 2025-07-23

Description: To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
Drug Trials Snapshot

Drug Name: Ekterly

Active Ingredient: sebetralstat

Approval Date: 2025-07-03

Description: To treat acute attacks of hereditary angioedema
Drug Trials Snapshot

Drug Name: Zegfrovy

Active Ingredient: sunvozertinib

Approval Date: 2025-07-02

Description: To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
Drug Trials Snapshot

Drug Name: Lynozyfic

Active Ingredient: linvoseltamab-gcpt

Approval Date: 2025-07-02

Description: To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

Drug Name: Andembry

Active Ingredient: garadacimab-gxii

Approval Date: 2025-06-16

Description: To prevent attacks of hereditary angioedema
Drug Trials Snapshot

Drug Name: Ibtrozi

Active Ingredient: taletrectinib

Approval Date: 2025-06-11

Description: To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
Drug Trials Snapshot

Drug Name: Enflonsia

Active Ingredient: clesrovimab-cfor

Approval Date: 2025-06-09

Description: To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season 
Drug Trials Snapshot

300×250 Ad Slot